The European Medicines Agency (EMA), the EU's drug regulator, is expected to decide in early October on the possible use of a booster dose of the Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine, Reuters news agency reported on Thursday, citing a source with direct knowledge of the matter.
According to the source, this will be the EMA's first decision on COVID-19 vaccine boosters.
The regulator said on 6 September that it had begun its evaluation of data submitted by Pfizer and BioNTech for a booster dose to be given six months after the second dose in people 16 years of age and older.
Iterion Therapeutics reports first patient dosed in clinical study of tegavivint
FDA accepts Takeda's oveporexton NDA with priority review for narcolepsy type 1
Innocan Pharma reports findings from clinical study of LPT-CBD in dogs
Lunai Bioworks starts new oncology collaboration with clinical-stage partner
Median Technologies secures FDA clearance for AI lung cancer screening software
Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia
Ascentage Pharma receives China IND clearance for BTK degrader APG‑3288
FDA issues EUA for Boehringer Ingelheim's IVOMEC (ivermectin) 1% Injection
Cumberland Pharmaceuticals secures FDA Fast Track status for DMD heart‑disease therapy ifetroban
Hologic receives FDA approval for Aptima HPV assay as primary screening option
AbbVie submits FDA and EMA applications for new upadacitinib indication in NSV
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer